Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program
Standard
Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. / Chao, Tze-Fan; Hong, Keun-Sik; Lee, Byung-Chul; De Caterina, Raffaele; Kirchhof, Paulus; Reimitz, Paul-Egbert; Chen, Cathy; Unverdorben, Martin; Wang, Chun-Chieh.
in: J CHIN MED ASSOC, Jahrgang 84, Nr. 5, 01.05.2021, S. 485-490.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program
AU - Chao, Tze-Fan
AU - Hong, Keun-Sik
AU - Lee, Byung-Chul
AU - De Caterina, Raffaele
AU - Kirchhof, Paulus
AU - Reimitz, Paul-Egbert
AU - Chen, Cathy
AU - Unverdorben, Martin
AU - Wang, Chun-Chieh
N1 - Copyright © 2021, the Chinese Medical Association.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - BACKGROUND: Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists as the standard of care for stroke prevention in patients with atrial fibrillation (AF). However, DOAC prescriptions at dosages that do not adhere to labeling are common in daily practice. This analysis from the observational Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program focuses on edoxaban-treated patients from South Korea and Taiwan to identify patient baseline characteristics that may be associated with non-recommended dosing.METHODS: We report baseline data from ETNA-AF, including patient demographics, clinical characteristics, and bleeding/stroke history of patients receiving recommended or non-recommended edoxaban dosing.RESULTS: A total of 2677 patients were enrolled. Among 1543 patients who did not meet dose-reduction criteria, 1033 (66.9%) were prescribed the recommended 60-mg dose, and 510 (33.1%) were prescribed the non-recommended 30-mg dose. Among 1134 patients meeting ≥1 of the dose-reduction criteria, 863 (76.1%) were prescribed the recommended 30-mg dose; 271 (23.9%) were prescribed the nonrecommended 60-mg dose. Compared with the recommended 60-mg group, the nonrecommended 30-mg group had a higher proportion of patients aged ≥75 years, higher stroke and bleeding risks, and a history of major bleeding. The non-recommended 60-mg group had a lower proportion of patients aged ≥75 years, a higher history of stroke, and lower history of bleeding compared with the recommended 30-mg group.CONCLUSION: The baseline data from ETNA-AF indicate that physicians take patient clinical characteristics (e.g., bleeding risks) into consideration when deviating from the dosing recommendation per label.
AB - BACKGROUND: Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists as the standard of care for stroke prevention in patients with atrial fibrillation (AF). However, DOAC prescriptions at dosages that do not adhere to labeling are common in daily practice. This analysis from the observational Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program focuses on edoxaban-treated patients from South Korea and Taiwan to identify patient baseline characteristics that may be associated with non-recommended dosing.METHODS: We report baseline data from ETNA-AF, including patient demographics, clinical characteristics, and bleeding/stroke history of patients receiving recommended or non-recommended edoxaban dosing.RESULTS: A total of 2677 patients were enrolled. Among 1543 patients who did not meet dose-reduction criteria, 1033 (66.9%) were prescribed the recommended 60-mg dose, and 510 (33.1%) were prescribed the non-recommended 30-mg dose. Among 1134 patients meeting ≥1 of the dose-reduction criteria, 863 (76.1%) were prescribed the recommended 30-mg dose; 271 (23.9%) were prescribed the nonrecommended 60-mg dose. Compared with the recommended 60-mg group, the nonrecommended 30-mg group had a higher proportion of patients aged ≥75 years, higher stroke and bleeding risks, and a history of major bleeding. The non-recommended 60-mg group had a lower proportion of patients aged ≥75 years, a higher history of stroke, and lower history of bleeding compared with the recommended 30-mg group.CONCLUSION: The baseline data from ETNA-AF indicate that physicians take patient clinical characteristics (e.g., bleeding risks) into consideration when deviating from the dosing recommendation per label.
KW - Administration, Oral
KW - Aged
KW - Anticoagulants/administration & dosage
KW - Atrial Fibrillation/drug therapy
KW - Databases, Factual
KW - Factor Xa Inhibitors/administration & dosage
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Pyridines/administration & dosage
KW - Republic of Korea
KW - Stroke/prevention & control
KW - Taiwan
KW - Thiazoles/administration & dosage
U2 - 10.1097/JCMA.0000000000000516
DO - 10.1097/JCMA.0000000000000516
M3 - SCORING: Journal article
C2 - 33742992
VL - 84
SP - 485
EP - 490
JO - J CHIN MED ASSOC
JF - J CHIN MED ASSOC
SN - 1726-4901
IS - 5
ER -